JBI-802, novel dual inhibitor of LSD1-HDAC6 for treatment of cancer

被引：10
|
作者：
Sivanandhan, Dhanalakshmi [1 ]
Rajagopal, Sridharan [1 ]
Nair, Sreekala [2 ]
Basavaprabhu, B. [2 ]
Dhkar, Reshma [2 ]
Viswakarma, Santosh [2 ]
Siddiqui, Amir [2 ]
Zainuddin, Mohd [2 ]
Rudresh, G. [2 ]
Daram, Prashanthi [2 ]
Mohire, Sunil [2 ]
Krishnakumar, V [2 ]
机构：
[1] Jubilant Therapeut Ltd, Yardley, PA USA
[2] Jubilant Biosys Ltd, Bangalore, Karnataka, India
来源：
CANCER RESEARCH | 2020年 / 80卷 / 16期
关键词：
D O I：
10.1158/1538-7445.AM2020-1756
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1756
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Discovery of a Novel and Potent Dual-Targeting Inhibitor of ATM and HDAC2 Through Structure-Based Virtual Screening for the Treatment of Testicular Cancer
    Ruan, Yashi
    Guan, Lixia
    Wang, Yuting
    Geng, Yifei
    Wang, Xiaoran
    Niu, Miao-Miao
    Yang, Li
    Xu, Cen
    Xu, Zhen
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2024, 18 : 5283 - 5297
  • [42] ZY0511, a Novel and Selective LSD1 Inhibitor, Suppresses the Growth and Metastasis of Ovarian Cancer
    Zhao, Yinglan
    Lei, Tao
    Zhou, Yue
    Liu, Huan
    Gou, Kun
    Zuo, Zeping
    Sang, Na
    Liu, Chunqi
    You, Junpeng
    CANCER SCIENCE, 2021, 112 : 540 - 540
  • [43] Discovery of rafoxanide as a dual CDK4/6 inhibitor for the treatment of skin cancer
    Shi, Xinan
    Li, Hongjian
    Shi, Anhua
    Yao, Hong
    Ke, Kunbin
    Dong, Chao
    Zhu, Ying
    Qin, Yi
    Ding, Ying
    He, Yan Hong
    Liu, Xu
    Li, Ling
    Lei, Ling
    Hai, Qingshan
    Chen, Wei
    Leung, Kwong-Sak
    Wong, Man-Hon
    Kung, Hsiang-Fu
    Lin, Marie Chia-Mi
    ONCOLOGY REPORTS, 2018, 40 (03) : 1592 - 1600
  • [44] Development of novel tetrahydroisoquinoline-hydroxamate conjugates as potent dual SERDs/HDAC inhibitors for the treatment of breast cancer
    Luo, Guoshun
    Lin, Xin
    Ren, Shengnan
    Wu, Shuangjie
    Wang, Xin
    Ma, Luyu
    Xiang, Hua
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2021, 226
  • [45] A novel HDAC6 inhibitor exerts an anti-cancer effect by triggering cell cycle arrest and apoptosis in gastric cancer
    Dong, Jing
    Zheng, Nan
    Wang, Xue
    Tang, Chu
    Yan, Ping
    Zhou, Hai-bing
    Huang, Jian
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2018, 828 : 67 - 79
  • [46] Preclinical evaluation of the compound 4SC-202, a combined LSD1-and HDAC-inhibitor, for the treatment of cutaneous T cell lymphoma
    Wobser, M.
    Weber, A.
    Glunz, A.
    Kohlhof, H.
    Brzezinski, V.
    Goebeler, M.
    Schrama, D.
    Houben, R.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2015, 13 : 1 - 1
  • [47] HDAC1/3 dual selective inhibitors - New therapeutic agents for the potential treatment of cancer
    Li, Xiaoyang
    Xu, Wenfang
    DRUG DISCOVERIES AND THERAPEUTICS, 2014, 8 (05): : 225 - 228
  • [48] MPT0G521 AS A DUAL INHIBITOR OF LSD1 AND HDAC: A POTENTIAL THERAPEUTIC AGENT AGAINST PARENTAL AND TEMOZOLOMIDE-RESISTANT GLIOBLASTOMA MULTIFORME
    Lo, Wei-Lun
    Chuang, Jian-Yin
    Wu, Ming-Shao
    NEURO-ONCOLOGY, 2024, 26
  • [49] Discovery and optimization of dihydropteridone derivatives as novel PLK1 and BRD4 dual inhibitor for the treatment of cancer
    Liu, Jiuyu
    Huang, Jingxuan
    Wang, Kang
    Li, Yuan
    Li, Chunting
    Zhu, Yanli
    He, Xinzi
    Zhang, Yating
    Zhao, Yanfang
    Hu, Changliang
    Xi, Zhiguo
    Tong, Minghui
    Li, Zhiwei
    Gong, Ping
    Hou, Yunlei
    BIOORGANIC & MEDICINAL CHEMISTRY, 2024, 101
  • [50] Preclinical investigation of the novel histone deacetylase (HDAC) inhibitor AR-42 in the treatment of cancer-induced cachexia
    Tseng, Yu-Chou
    Kulp, Samuel
    Lai, I-Lu
    He, Wei
    Bundschuh, Ralf
    Frankhouser, David
    Yan, Pearlly
    Guttridge, Denis
    Marcucci, Guido
    Chen, Ching-Shih
    Bekaii-Saab, Tanios
    CANCER RESEARCH, 2014, 74 (19)
12345